| Ebony Steele, LVN | |
|
19622 Atherton Bend Ln, Cypress, TX 77429-6153 | |
| (346) 412-8418 | |
| (346) 857-0627 |
| Full Name | Ebony Steele |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 19622 Atherton Bend Ln, Cypress, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508244534 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 158135 (Ohio) | Secondary |
| 164W00000X | Licensed Practical Nurse | 331261 (Texas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ebony Steele, LVN 19622 Atherton Bend Ln, Cypress, TX 77429-6153 Ph: (346) 412-8418 | Ebony Steele, LVN 19622 Atherton Bend Ln, Cypress, TX 77429-6153 Ph: (346) 412-8418 |
News Archive
ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.
Longer sitting times were associated with higher levels of heart disease risk among overweight and obese post-menopausal women overall, according to new research published today in the Journal of the American Heart Association, the open access journal of the American Heart Association.
The state Health Department reports the rate of health care spending in Minnesota has slowed to its lowest point since 1997. Health care costs are still rising, but at a much slower pace - 2.2 percent between 2009 and 2010. State Health Economist Stefan Gildemeister said the recession was a major factor in why Minnesotans spent less on health care. He said many lost their insurance when they lost their jobs and others who kept their jobs were more cautious.
Drug-eluting stents were safe and superior to bare metal stents in preventing death and heart attacks among 262,700 "real-world" patients enrolled in a nationwide registry of cardiovascular disease, according to researchers from Duke University Medical Center.
Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.
› Verified 2 days ago
Laneisha Wilkerson, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 15915 Mountian Willow Way, Cypress, TX 77429 Phone: 484-942-7959 |